Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab Dose Schedules in Smoldering Multiple Myeloma
NCT02316106Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2015
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of daratumumab in smoldering multiple myeloma (SMM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Complete Response at 1.58 years and Progressive Disease or Death Rate at 2.07 years. Started May 2015; status: completed.
02
Drugs
daratumumab
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT02316106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02316106.